[go: up one dir, main page]

DK3166973T3 - Immunstimulerende monoklonale antistoffer mod human interleukin-2 - Google Patents

Immunstimulerende monoklonale antistoffer mod human interleukin-2 Download PDF

Info

Publication number
DK3166973T3
DK3166973T3 DK15759938.2T DK15759938T DK3166973T3 DK 3166973 T3 DK3166973 T3 DK 3166973T3 DK 15759938 T DK15759938 T DK 15759938T DK 3166973 T3 DK3166973 T3 DK 3166973T3
Authority
DK
Denmark
Prior art keywords
immunstimulating
monoclonal antibodies
antibodies against
against human
human interleukin
Prior art date
Application number
DK15759938.2T
Other languages
English (en)
Inventor
Onur Boyman
Natalia Arenas-Ramirez
Chao Zou
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK3166973T3 publication Critical patent/DK3166973T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/246IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15759938.2T 2014-07-10 2015-07-10 Immunstimulerende monoklonale antistoffer mod human interleukin-2 DK3166973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (1)

Publication Number Publication Date
DK3166973T3 true DK3166973T3 (da) 2020-04-06

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15759938.2T DK3166973T3 (da) 2014-07-10 2015-07-10 Immunstimulerende monoklonale antistoffer mod human interleukin-2

Country Status (9)

Country Link
US (2) US10894828B2 (da)
EP (2) EP3693389B1 (da)
JP (1) JP7209464B2 (da)
CN (1) CN106604932B (da)
AU (1) AU2015287227B2 (da)
CA (1) CA2954476C (da)
DK (1) DK3166973T3 (da)
ES (2) ES2989669T3 (da)
WO (1) WO2016005950A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43859A (fr) 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3585404A4 (en) * 2017-02-23 2021-04-14 City of Hope METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD)
SG11201908744PA (en) 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
AU2018271751B2 (en) * 2017-05-25 2021-04-01 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023509991A (ja) 2020-01-13 2023-03-10 シンアフィックス ビー.ブイ. 抗体及び免疫細胞エンゲージャーのコンジュゲート
CA3166139A1 (en) * 2020-02-16 2021-08-19 Inbar AMIT Engineered anti-il-2 antibodies
CA3189257A1 (en) * 2020-08-18 2022-02-24 Universitat Zurich A cd25-biased anti-il-2 antibody
EP4288108A1 (en) 2021-02-08 2023-12-13 Synaffix B.V. Multifunctional antibodies
KR20240082411A (ko) 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559A (zh) * 2025-01-22 2025-05-02 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340853C (en) 1983-12-23 1999-12-21 Hsiang-Fu Kung Purification of recombinant interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ.ホフマン ― ラ ロシュ アーゲー Il−2蛋白質に対するモノクロ−ナル抗体
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
SG170001A1 (en) * 2006-02-16 2011-04-29 Nascent Biolog Inc Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
RS54685B1 (sr) 2010-08-12 2016-08-31 Eli Lilly And Company ANTI-N3pGlu AMILOID BETA PEPTID ANTITELA I NJIHOVE UPOTREBE
PL3075745T3 (pl) 2011-02-10 2019-07-31 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ5ac特異的ヒト化抗体およびその利用
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
AU2015287227A1 (en) 2017-02-09
WO2016005950A1 (en) 2016-01-14
EP3693389B1 (en) 2024-09-04
EP3693389A9 (en) 2021-04-07
JP2017525343A (ja) 2017-09-07
AU2015287227A8 (en) 2017-02-16
AU2015287227B2 (en) 2021-02-18
CA2954476C (en) 2023-09-19
EP3693389A1 (en) 2020-08-12
US20210230269A1 (en) 2021-07-29
ES2779977T3 (es) 2020-08-21
EP3166973A1 (en) 2017-05-17
US10894828B2 (en) 2021-01-19
CN106604932B (zh) 2024-12-10
ES2989669T3 (es) 2024-11-27
JP7209464B2 (ja) 2023-01-20
EP3693389C0 (en) 2024-09-04
CA2954476A1 (en) 2016-01-14
US20170183403A1 (en) 2017-06-29
CN106604932A (zh) 2017-04-26
EP3166973B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
IL272274A (en) B7-h4 antibodies and methods of use thereof
IL272227A (en) Anti-tigit antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
HUE060019T2 (hu) Anti-LAG3 antitestek
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
DK3166973T3 (da) Immunstimulerende monoklonale antistoffer mod human interleukin-2
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
BR112017001385A2 (pt) anticorpos anti-pd-1
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
HUE060878T2 (hu) Anti-transztiretin antitestek
IL262776A (en) Humanized anti-il-1r3 antibodies
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
EP3684806A4 (en) NEW ANTI-CD3EPSILON ANTIBODIES
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3606961T3 (da) Garp-tgf-beta-antistoffer
IL291164A (en) Anti-nme antibody
PL3215530T3 (pl) Ulepszone przeciwciała anty-il-6
DK3154583T3 (da) Humane monoklonale antistoffer mod gangliosid gd2
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3452515T3 (da) Her-2-bindende antistoffer
DK3126391T3 (da) ANTISTOFFER MOD HPA-1a
LT3178931T (lt) Anti-orai1 antikūnas